Benchmark Share Discussion Threads

[steveo18] 12/2/2015 09:51

I'm getting ready to buy

[nw99] 12/2/2015 09:51

Huge trades going thro

[nw99] 08/2/2015 18:33

Shs mag still bullish

[cestnous] 03/2/2015 15:06

Invesco goes over 14%

[nw99] 02/2/2015 07:07

Cash enhancing acquisition

[exbroker] 30/1/2015 18:36

It looks as if Cenkos has cleaned up the seller at the 100 level, I think they are still 2 way but on what basis I am not sure, nice move though. I was at the lunch on Tuesday and all seems to be going ok all they boys have to do now is deliver......

[cestnous] 30/1/2015 15:50

Nice recovery from the big drop. Analysts never seem to get it right.

[janeann] 30/1/2015 12:58

buys or sells - they were at the mid price?!

[gucci] 30/1/2015 12:53

big buys coming in now
last mm om 107

[gucci] 30/1/2015 12:08

seems mm not giving more than 1500 shares at a time

[phowdo] 30/1/2015 12:06

Im a little surprised at the demand post finals but possible its a top quality company that will always be "expensive".

[janeann] 30/1/2015 12:03

just added a few; will hope to see an rns re the large exchange of shares earlier

[gucci] 30/1/2015 11:59

taking off

[nw99] 30/1/2015 10:55

Chart suggests a good rebound off support

[gucci] 30/1/2015 10:32

l2 firming

[nw99] 30/1/2015 10:18

Huge buying what's going on ?

[gucci] 30/1/2015 09:56

very big buys today

[cestnous] 30/1/2015 08:25

I.C. today

A year ago, animal health business Benchmark Holdings (BMK) had just joined London’s junior market, raising £25m of new cash in the process. Fast-forward 12 months and the top line has grown by more than a quarter. That’s mainly thanks to a 22 per cent increase in revenues from animal health – by far the company’s biggest division – to which a full year of sales from Benchmark’s core sea lice treatment, Salmosan, in Chile was the biggest contributor.
But soaring costs left adjusted cash profits down 11 per cent at £6.6m – and this figure doesn’t even include £4.7m of research and development spending. Clearly, the company is in growth mode. Last year it added 17 products to its future product pipeline, bringing the total to 47, and increased the employee headcount by 40 per cent.
The group was also on the acquisition trail last year. It picked up several aquaculture vaccine assets from US competitor Zoetis for $3m (£2m) in February. Then, post period-end, it bought Norwegian group SalmoBreed and Icelandic outfit Stofnfiskur for close to £40m, thus creating a brand-new breeding and genetics division.
Analysts at Cenkos Securities expect pretax profits of £4.4m this year, giving EPS of 4.2p, up from £3.2m and 3.9p in 2014.
C We earmarked Benchmark as “one to watch” following interim results last June, and these numbers confirm a strong top-line growth profile. But costs are weighing on the bottom line, and the shares trade on 23 times earnings. This could be a slow-burner. HR
Hold

[gucci] 28/1/2015 09:46

is the presentation this morning?
lets hope for some positive injection into this

[woodcutter] 27/1/2015 20:27

The adjusted eps is in line with forecasts however there's £2.7m of R&D which has been treated as exceptional costs. i'd be inclined to view R&D as an annual cost and therefore not so exceptional. Add that figure back in to the P&L as a cost and it doesn't look so good imv.

As i noted i'd like to see at least the next reported figures and the effects on revenue and profit growth from the wider group including the acquisitions.

It has further to fall for me to justify an investment.

woody

[hydrus] 27/1/2015 09:23

Fair points although the EPS is in line with broker expectations.

[woodcutter] 27/1/2015 09:14

thought about investing a number of times but held back. After today's announcement it seems it was a wise move. The increase in IPO shares has clearly impacted the eps.

The additional siginificant employee numbers as a result of acquisitions will also add to overhead costs and there'll need to be substantial improvement in revenue growth in order to sustain those numbers.

There's no question it's a growth industry and they're at the forefront of the market but i'd like to see improvement or perhaps more clarity in the financials before investing.

aimho woody

[gucci] 27/1/2015 09:02

What's happened here????